SuperworthTG Therapeutics TGTX
- Market cap
- $8.3B
- PE
- 19.8×
- 1y median 19.4×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 10.4×
- EV/EBIT
- 62.2×
- Revenue, 12 months
- $799.5M
- +76% on a year ago
- Net margin
- 55.2%
- Free cash flow yield
- 0.2%
TG Therapeutics trades at 19.8× trailing earnings, near its ten-year median. Revenue was $799.5M over the last twelve months, up 76% on a year earlier with a 55% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $165.8M+176299% | $44M+54864% | $63.5M+714% | $73.5M+357% | $83.9M−49% | $108.2M+146% | $120.9M+90% | $141.1M+92% | $161.7M+93% | $192.6M+78% | $204.9M+70% | $240.3M+70% | |
| Cost of revenue | $3.5M+175350% | $7.9M+261700% | $5.4M+535% | $8.3M+335% | $9.3M+166% | $15.4M+96% | $15.5M+186% | $18.9M+128% | $28.1M+201% | $38.1M+148% | $33.5M+116% | $41.2M+118% |
| Gross profit | $162.3M+176320% | $36.1M+46805% | $58M+736% | $65.2M+360% | $74.5M−54% | $92.8M+157% | $105.3M+82% | $122.2M+88% | $133.6M+79% | $154.4M+66% | $171.4M+63% | $199.1M+63% |
| R&D | $14.8M−29% | $17.4M−41% | $32.7M+106% | $17.6M−38% | $20.1M+37% | $23.9M+37% | $46.4M+42% | $31.8M+81% | $40.9M+103% | $41.2M+73% | $48.4M+4% | $95.3M+200% |
| SG&A | $32.8M+130% | $31.2M+38% | $34.6M+23% | $38.8M+26% | $42M+28% | $39M+25% | $50.3M+46% | $55.6M+43% | $63.4M+51% | $62.7M+61% | $88.2M+75% | $82.1M+48% |
| $114.8M | −$12.5M−76% | −$9.3M−75% | $8.8M | $12.4M−89% | $29.9M | $8.6M | $34.8M+295% | $29.4M+136% | $50.5M+69% | $34.8M+304% | $21.7M−38% | |
| Interest expense | $3.7M+125% | $2.4M−15% | $2.3M−20% | $4M+10% | $10.8M+192% | $7.1M+191% | $6.8M+195% | $6.7M+69% | $6.7M−38% | $6.5M−8% | $7.7M+14% | $16.6M+147% |
| Pre-tax income | $113.9M | −$14M | −$10.7M−73% | $6.6M | $4.3M−96% | $25.5M | $5.5M | $30.9M+372% | $25.9M+507% | $45.1M+77% | $20.4M+272% | $10.2M−67% |
| $0 | $390K | $29K | −$328K | $388K | $2.1M+444% | $408K+1307% | $2.7M | −$365M | $22.1M+939% | $586K+44% | $2.5M−10% | |
| Net income | $113.9M | −$14.4M−73% | −$10.7M−73% | $6.9M | $3.9M−97% | $23.3M | $5.1M | $28.2M+310% | $390.9M+9975% | $23M−1% | $19.8M+291% | $7.8M−72% |
| $0.73 | −$0.10−74% | −$0.07−75% | $0.04 | $0.02−97% | $0.15 | $0.03 | $0.17+325% | $2.43+12050% | $0.14−7% | $0.12+300% | $0.05−71% | |
| 155.9M+15% | 143.1M+4% | 146.2M+4% | 159.4M+13% | 160.7M+3% | 160.2M+12% | 162.8M+11% | 162.6M+2% | 161M+0% | 159.4M−1% | 160.1M−2% | 157.3M−3% |
Gross profit: 17 periods, Q1 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 14 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q2 FY10: not printed by the filing, worked out from its own lines. 12 periods, Q4 FY12 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | 3.0× | +13% | 20.4% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $6.9B | 97.0× | 44.6× | 5.8× | +15% | 8.1% |
More on TG Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 317Healthcare stocks with the highest profit margins
- #4of 84Large drugmakers with the highest profit margins
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .